Leena Kylänpää
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Leena Kylänpää has a total of 84 co-authors. Here are the top co-authors by number of shared publications:
- Marianne Udd
Gastrointestinal Surgery, Helsinki University Central Hospital, Helsinki, Finland
5 shared publications - Andrea Anderloni
Università di Pavia, Italy
3 shared publications - David Michaël de Jong
Department of Gastroenterology and Hepatology, Erasmus MC University Medical Center, Rotterdam, The Netherlands
3 shared publications - Marco J. Bruno
Department of Gastroenterology and Hepatology, Erasmus MC University Medical Center, Rotterdam, The Netherlands
3 shared publications - Mark Ellrichmann
University Hospital Oldenburg, GERMANY
3 shared publications - Mia Rainio
Department of Abdominal Surgery, Helsinki University Hospital
3 shared publications
Latest Publications
- Open Access
- 13 January 2026
- Published by Georg Thieme Verlag KG in Endoscopy International Open
- Vol. 14 (CP)
Cholangioscopy in the Diagnostic and Therapeutic Work-Up of Intraductal Papillary Neoplasms of the Bile Duct: A Systematic Review and Meta-Analysis
Background Intraductal papillary neoplasms of the bile duct (IPNB) are rare and diagnostically challenging, particularly in assessing invasiveness and intraductal spread. Cholangioscopy offers promise through direct visualization and targeted biopsies. The aim of this study was to review the current literature on the role of cholangioscopy in diagnosing IPNB, assessment of disease extent, and therapeutic applications. Methods The EMBASE, Medline Ovid, Web of Science, Cochrane CENTRAL, and Google Scholar databases were systematically searched for articles. Eligible articles investigated cohorts of patients who underwent cholangioscopy for (suspected) IPNB. Results In all, 17 studies comprising 224 patients were included. Despite substantial heterogeneity, cholangioscopy demonstrated high technical success and visualization rates, with a low adverse event rate. Several cholangioscopy-based classification systems describing mucosal and microvascular patterns of IPNB have been proposed, but none are widely adopted. The impact on clinical decision-making was primarily related to confirming tumour invasiveness and assessing preoperative intraductal extent. Two studies showed that cholangioscopy is feasible for therapeutic purposes in IPNB, such as polypectomy and electrocoagulation. Conclusion Cholangioscopy is increasingly important in the diagnosis and management of IPNB, but standardized visual criteria and consistent biopsy accuracy remain lacking. Therapeutic applications are uncommon yet appear feasible in selected cases. Given the rarity of IPNB, collaborative registries and pooled observational data are needed to support standardized clinical protocols.
- 13 January 2026
- Published by Georg Thieme Verlag KG in Endoscopy International Open
- Vol. 14 (CP)
Open AccessCholangioscopy in the Diagnostic and Therapeutic Work-Up of Intraductal Papillary Neoplasms of the Bile Duct: A Systematic Review and Meta-Analysis
Background Intraductal papillary neoplasms of the bile duct (IPNB) are rare and diagnostically challenging, particularly in assessing invasiveness and intraductal spread. Cholangioscopy offers promise through direct visualization and targeted biopsies. The aim of this study was to review the current literature on the role of cholangioscopy in diagnosing IPNB, assessment of disease extent, and therapeutic applications. Methods The EMBASE, Medline Ovid, Web of Science, Cochrane CENTRAL, and Google Scholar databases were systematically searched for articles. Eligible articles investigated cohorts of patients who underwent cholangioscopy for (suspected) IPNB. Results In all, 17 studies comprising 224 patients were included. Despite substantial heterogeneity, cholangioscopy demonstrated high technical success and visualization rates, with a low adverse event rate. Several cholangioscopy-based classification systems describing mucosal and microvascular patterns of IPNB have been proposed, but none are widely adopted. The impact on clinical decision-making was primarily related to confirming tumour invasiveness and assessing preoperative intraductal extent. Two studies showed that cholangioscopy is feasible for therapeutic purposes in IPNB, such as polypectomy and electrocoagulation. Conclusion Cholangioscopy is increasingly important in the diagnosis and management of IPNB, but standardized visual criteria and consistent biopsy accuracy remain lacking. Therapeutic applications are uncommon yet appear feasible in selected cases. Given the rarity of IPNB, collaborative registries and pooled observational data are needed to support standardized clinical protocols.
- Open Access
- 23 May 2025
- Published by Georg Thieme Verlag KG in Endoscopy
- Vol. 57 (11) , 1220-1229
The value of cholangioscopy-guided bite-on-bite (-on bite) biopsies in indeterminate biliary duct strictures
Background Digital single-operator cholangioscopy (dSOC) has improved the diagnostic accuracy of indeterminate biliary duct strictures (IBDS) through targeted intraductal biopsy sampling. However, the optimal biopsy technique remains uncertain. Methods This international, multicenter, prospective interventional study (November 2020–August 2022) included patients with IBDS undergoing dSOC. Stricture sampling involved obtaining at least four single biopsies and at least one bite-on-bite biopsy (BBB) in all patients. Definitive diagnosis was established by pathology outcomes and 1-year clinical follow-up. The primary outcome was the accuracy of both biopsy techniques. Results 89 patients were included, with 76 hilar strictures and 13 distal strictures. Technical success for obtaining adequate tissue samples was 82/89 (92.1 %) for single biopsies and 78/89 (87.6 %) for BBB. Malignancy was confirmed in 31/82 (37.8 %) and 29/78 (37.2 %) cases in single biopsies and BBB, respectively. Among 76 patients in whom both techniques were successful, pathology results were discordant in three cases (3.9 %), primarily due to understaging by BBB. Among 82 patients with complete follow-up, malignancy was confirmed in 51 (62.2 %). Sensitivity, specificity, and accuracy for malignancy or high grade dysplasia were 66.0 %, 100 %, and 78.8 % for single biopsies, and 63.8 %, 100 %, and 77.6 % for BBB, respectively. Sensitivity and accuracy were significantly decreased after stent placement or intraductal tissue acquisition during prior ERCP. The number of BBBs did not impact sensitivity or accuracy. Conclusions BBB did not outperform at least four single biopsies for IBDS. Prior manipulation of IBDS, through stent placement or prior tissue acquisition, was associated with a decreased diagnostic yield.
- 23 May 2025
- Published by Georg Thieme Verlag KG in Endoscopy
- Vol. 57 (11) , 1220-1229
Open AccessThe value of cholangioscopy-guided bite-on-bite (-on bite) biopsies in indeterminate biliary duct strictures
Background Digital single-operator cholangioscopy (dSOC) has improved the diagnostic accuracy of indeterminate biliary duct strictures (IBDS) through targeted intraductal biopsy sampling. However, the optimal biopsy technique remains uncertain. Methods This international, multicenter, prospective interventional study (November 2020–August 2022) included patients with IBDS undergoing dSOC. Stricture sampling involved obtaining at least four single biopsies and at least one bite-on-bite biopsy (BBB) in all patients. Definitive diagnosis was established by pathology outcomes and 1-year clinical follow-up. The primary outcome was the accuracy of both biopsy techniques. Results 89 patients were included, with 76 hilar strictures and 13 distal strictures. Technical success for obtaining adequate tissue samples was 82/89 (92.1 %) for single biopsies and 78/89 (87.6 %) for BBB. Malignancy was confirmed in 31/82 (37.8 %) and 29/78 (37.2 %) cases in single biopsies and BBB, respectively. Among 76 patients in whom both techniques were successful, pathology results were discordant in three cases (3.9 %), primarily due to understaging by BBB. Among 82 patients with complete follow-up, malignancy was confirmed in 51 (62.2 %). Sensitivity, specificity, and accuracy for malignancy or high grade dysplasia were 66.0 %, 100 %, and 78.8 % for single biopsies, and 63.8 %, 100 %, and 77.6 % for BBB, respectively. Sensitivity and accuracy were significantly decreased after stent placement or intraductal tissue acquisition during prior ERCP. The number of BBBs did not impact sensitivity or accuracy. Conclusions BBB did not outperform at least four single biopsies for IBDS. Prior manipulation of IBDS, through stent placement or prior tissue acquisition, was associated with a decreased diagnostic yield.
- 13 March 2025
- Published by Taylor & Francis in Scandinavian Journal of Gastroenterology
- Vol. 60 (4) , 386-393
Stone density can predict the number of ESWL treatments needed in patients with pancreatic duct calculi
Extracorporeal shock wave lithotripsy (ESWL) with endotherapy (ET) is the first-line treatment in patients with chronic pancreatitis (CP) and main pancreatic duct stone (PDS). Our study aimed to evaluate factors that predict the outcome of ESWL in CP patients with PDS. We retrospectively analyzed data of 166 patients with CP and radiopaque PDS. Computed tomography (CT) images were evaluated for stone density, stone size, main pancreatic duct (MPD) size, and skin-to-stone distance (SSD). Long-term pain relief results were determined via telephone interview in 100 patients. Mean stone density (MSD) > 1336 HU predicted the need to perform more than one ESWL session (odds ratio [OR]: 1.002; 95% confidence interval [CI]: 1.001 to 1.003; p = 0.002), cut-off 1336 HU yielding 71% sensitivity and 65% specificity. Denser stones required more ESWL and following ET, with ≥4 ET sessions resulting in better technical success. (OR: 3.222; 95% CI: 1.240 to 8.371; p = 0.016). Overall technical success (complete stone fragmentation in ESWL or placing a stent past the stone in ET) rate was 81.3%. Clinical success (complete or partial pain relief at the end of the treatments) rate was 83.7% and remained at the same level also in the long-term follow-up (median 5.5 years). Stone size, MPD size, or SSD were not associated with any of the study outcomes. Higher MSD than 1336 HU predicts the need for more than one ESWL and ET sessions to fragment the stone and clear the duct, but when successful the long-term result is favorable.
- 13 March 2025
- Published by Taylor & Francis in Scandinavian Journal of Gastroenterology
- Vol. 60 (4) , 386-393
Stone density can predict the number of ESWL treatments needed in patients with pancreatic duct calculi
Extracorporeal shock wave lithotripsy (ESWL) with endotherapy (ET) is the first-line treatment in patients with chronic pancreatitis (CP) and main pancreatic duct stone (PDS). Our study aimed to evaluate factors that predict the outcome of ESWL in CP patients with PDS. We retrospectively analyzed data of 166 patients with CP and radiopaque PDS. Computed tomography (CT) images were evaluated for stone density, stone size, main pancreatic duct (MPD) size, and skin-to-stone distance (SSD). Long-term pain relief results were determined via telephone interview in 100 patients. Mean stone density (MSD) > 1336 HU predicted the need to perform more than one ESWL session (odds ratio [OR]: 1.002; 95% confidence interval [CI]: 1.001 to 1.003; p = 0.002), cut-off 1336 HU yielding 71% sensitivity and 65% specificity. Denser stones required more ESWL and following ET, with ≥4 ET sessions resulting in better technical success. (OR: 3.222; 95% CI: 1.240 to 8.371; p = 0.016). Overall technical success (complete stone fragmentation in ESWL or placing a stent past the stone in ET) rate was 81.3%. Clinical success (complete or partial pain relief at the end of the treatments) rate was 83.7% and remained at the same level also in the long-term follow-up (median 5.5 years). Stone size, MPD size, or SSD were not associated with any of the study outcomes. Higher MSD than 1336 HU predicts the need for more than one ESWL and ET sessions to fragment the stone and clear the duct, but when successful the long-term result is favorable.
- Open Access
- 24 July 2022
- Published by Taylor & Francis in Scandinavian Journal of Gastroenterology
- Vol. 58 (1) , 88-93
ACUTE PANCREATITIS in HELSINKI in 2016−2018: INCIDENCE, ETIOLOGY and RISK FACTORS - analysis of 1378 acute pancreatitis episodes in a Finnish normal population
Updated population-based studies on acute pancreatitis (AP) in Finland are lacking. Our aim was to evaluate the current data for AP in Helsinki.We performed an electronic health care records (EHRs)...
- 24 July 2022
- Published by Taylor & Francis in Scandinavian Journal of Gastroenterology
- Vol. 58 (1) , 88-93
Open AccessACUTE PANCREATITIS in HELSINKI in 2016−2018: INCIDENCE, ETIOLOGY and RISK FACTORS - analysis of 1378 acute pancreatitis episodes in a Finnish normal population
Updated population-based studies on acute pancreatitis (AP) in Finland are lacking. Our aim was to evaluate the current data for AP in Helsinki.We performed an electronic health care records (EHRs)...
- Open Access
- 20 July 2022
- Published by Georg Thieme Verlag KG in Endoscopy
- Vol. 55 (01) , 25-35
The role of pancreatoscopy in the diagnostic work-up of intraductal papillary mucinous neoplasms: a systematic review and meta-analysis
Background Confirming the diagnosis, invasiveness, and disease extent of intraductal papillary mucinous neoplasms (IPMNs) of the pancreas is challenging. The aim of this study was to summarize the literature on the efficacy and safety of peroral pancreatoscopy (POP) in the diagnosis of IPMN, including the impact of pre- and intraoperative POP on the management of IPMN. Methods The EMBASE, Medline Ovid, Web of Science, Cochrane CENTRAL, and Google Scholar databases were systematically searched for articles. Eligible articles investigated cohorts of patients who underwent POP for (suspected) IPMN. Results 25 articles were identified and included in this review; with 22 of these reporting on the diagnostic yield of POP in IPMN and 11 reporting on the effect of pre- or intraoperative POP on clinical decision-making. Cannulation and observation rates, and overall diagnostic accuracy were high across all studies. Frequently reported visual characteristics of IPMN were intraductal fish-egg-like lesions, hypervascularity, and granular mucosa. Overall, the adverse event rate was 12 %, primarily consisting of post-endoscopic retrograde cholangiopancreatography pancreatitis, with a pooled rate of 10 %, mostly of mild severity. Regarding the impact of POP on clinical decision-making, POP findings altered the surgical approach in 13 %–62 % of patients. Conclusion POP is technically successful in the vast majority of patients with (suspected) IPMN, has a consistently high diagnostic accuracy, but an adverse event rate of 12 %. Data on intraoperative pancreatoscopy are scarce, but small studies suggest its use can alter surgical management. Future studies are needed to better define the role of POP in the diagnostic work-up of IPMN. * Shared first authorship Received: 06 December 2021 Accepted after revision: 23 May 2022 Accepted Manuscript online: 03 June 2022 Article published online: 20 July 2022 © 2022. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution License, permitting unrestricted use, distribution, and reproduction so long as the original work is properly cited. (https://creativecommons.org/licenses/by/4.0/) Georg Thieme Verlag KG Rüdigerstraße 14, 70469 Stuttgart, Germany
- 20 July 2022
- Published by Georg Thieme Verlag KG in Endoscopy
- Vol. 55 (01) , 25-35
Open AccessThe role of pancreatoscopy in the diagnostic work-up of intraductal papillary mucinous neoplasms: a systematic review and meta-analysis
Background Confirming the diagnosis, invasiveness, and disease extent of intraductal papillary mucinous neoplasms (IPMNs) of the pancreas is challenging. The aim of this study was to summarize the literature on the efficacy and safety of peroral pancreatoscopy (POP) in the diagnosis of IPMN, including the impact of pre- and intraoperative POP on the management of IPMN. Methods The EMBASE, Medline Ovid, Web of Science, Cochrane CENTRAL, and Google Scholar databases were systematically searched for articles. Eligible articles investigated cohorts of patients who underwent POP for (suspected) IPMN. Results 25 articles were identified and included in this review; with 22 of these reporting on the diagnostic yield of POP in IPMN and 11 reporting on the effect of pre- or intraoperative POP on clinical decision-making. Cannulation and observation rates, and overall diagnostic accuracy were high across all studies. Frequently reported visual characteristics of IPMN were intraductal fish-egg-like lesions, hypervascularity, and granular mucosa. Overall, the adverse event rate was 12 %, primarily consisting of post-endoscopic retrograde cholangiopancreatography pancreatitis, with a pooled rate of 10 %, mostly of mild severity. Regarding the impact of POP on clinical decision-making, POP findings altered the surgical approach in 13 %–62 % of patients. Conclusion POP is technically successful in the vast majority of patients with (suspected) IPMN, has a consistently high diagnostic accuracy, but an adverse event rate of 12 %. Data on intraoperative pancreatoscopy are scarce, but small studies suggest its use can alter surgical management. Future studies are needed to better define the role of POP in the diagnostic work-up of IPMN. * Shared first authorship Received: 06 December 2021 Accepted after revision: 23 May 2022 Accepted Manuscript online: 03 June 2022 Article published online: 20 July 2022 © 2022. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution License, permitting unrestricted use, distribution, and reproduction so long as the original work is properly cited. (https://creativecommons.org/licenses/by/4.0/) Georg Thieme Verlag KG Rüdigerstraße 14, 70469 Stuttgart, Germany
- 1 September 2019
- Published by Elsevier in Pancreatology
- Vol. 19, S189-S190
Chronic use of statins and acetylsalicylic acid and incidence of post-ERCP acute pancreatitis. Data from the STARK project, a prospective international, multicenter, cohort study
- 1 September 2019
- Published by Elsevier in Pancreatology
- Vol. 19, S189-S190
Chronic use of statins and acetylsalicylic acid and incidence of post-ERCP acute pancreatitis. Data from the STARK project, a prospective international, multicenter, cohort study
- Open Access
- 1 October 2012
- Published by Oxford University Press (OUP) in Clinical Chemistry
- Vol. 58 (10) , 1494-1496
Reference Intervals for and Validation of Recalibrated Immunoassays for Trypsinogen-1 and Trypsinogen-2
- 1 October 2012
- Published by Oxford University Press (OUP) in Clinical Chemistry
- Vol. 58 (10) , 1494-1496
Open AccessReference Intervals for and Validation of Recalibrated Immunoassays for Trypsinogen-1 and Trypsinogen-2
- Open Access
- 1 November 2011
- Published by Oxford University Press (OUP) in Clinical Chemistry
- Vol. 57 (11) , 1506-1513
Specific Immunoassay Reveals Increased Serum Trypsinogen 3 in Acute Pancreatitis
BACKGROUND: Trypsinogen 3 is a minor trypsinogen isoform in the pancreas. In contrast with trypsin 1 and 2, trypsin 3 degrades pancreatic secretory trypsin inhibitor, which may lead to an excess of active trypsin and acute pancreatitis (AP). We developed an immunoassay for trypsinogen 3 and studied whether an assay of serum trypsinogen 3 is of clinical utility in the diagnosis of AP. METHODS: Monoclonal antibodies were generated using recombinant human trypsinogen 3 as the antigen and used to establish a sandwich-type immunoassay. We analyzed serum trypsinogen 3 concentrations in 82 patients with AP and 63 patients with upper abdominal pain (controls). The reference interval was determined using serum samples from 172 apparently healthy individuals. RESULTS: The measuring range of the trypsinogen 3 assay was 1.0–250 μg/L. Intra- and interassay CVs were <11%, and cross-reactivity with other trypsinogen isoenzymes was <0.1%. The median trypsinogen 3 concentration in serum from healthy individuals was <1.0 μg/L, and the upper reference limit was 4.4 μg/L. We observed increased trypsinogen 3 concentrations in patients with mild (median 9.5 μg/L) and severe (15.0 μg/L) AP; in both groups, the concentrations were significantly higher than in controls (median <1.0 μg/L) (P < 0.0001). In ROC analysis, the area under the curve of trypsinogen 3 for separation between AP and controls was 0.90 (P < 0.0001). CONCLUSIONS: We established for the first time a specific immunoassay for trypsinogen 3 using monoclonal antibodies. Patients with AP were found to have increased serum concentrations of trypsinogen 3. The availability of this assay will be useful for studies of the clinical utility of trypsinogen 3.
- 1 November 2011
- Published by Oxford University Press (OUP) in Clinical Chemistry
- Vol. 57 (11) , 1506-1513
Open AccessSpecific Immunoassay Reveals Increased Serum Trypsinogen 3 in Acute Pancreatitis
BACKGROUND: Trypsinogen 3 is a minor trypsinogen isoform in the pancreas. In contrast with trypsin 1 and 2, trypsin 3 degrades pancreatic secretory trypsin inhibitor, which may lead to an excess of active trypsin and acute pancreatitis (AP). We developed an immunoassay for trypsinogen 3 and studied whether an assay of serum trypsinogen 3 is of clinical utility in the diagnosis of AP. METHODS: Monoclonal antibodies were generated using recombinant human trypsinogen 3 as the antigen and used to establish a sandwich-type immunoassay. We analyzed serum trypsinogen 3 concentrations in 82 patients with AP and 63 patients with upper abdominal pain (controls). The reference interval was determined using serum samples from 172 apparently healthy individuals. RESULTS: The measuring range of the trypsinogen 3 assay was 1.0–250 μg/L. Intra- and interassay CVs were <11%, and cross-reactivity with other trypsinogen isoenzymes was <0.1%. The median trypsinogen 3 concentration in serum from healthy individuals was <1.0 μg/L, and the upper reference limit was 4.4 μg/L. We observed increased trypsinogen 3 concentrations in patients with mild (median 9.5 μg/L) and severe (15.0 μg/L) AP; in both groups, the concentrations were significantly higher than in controls (median <1.0 μg/L) (P < 0.0001). In ROC analysis, the area under the curve of trypsinogen 3 for separation between AP and controls was 0.90 (P < 0.0001). CONCLUSIONS: We established for the first time a specific immunoassay for trypsinogen 3 using monoclonal antibodies. Patients with AP were found to have increased serum concentrations of trypsinogen 3. The availability of this assay will be useful for studies of the clinical utility of trypsinogen 3.
- 10 September 2011
- Published by Springer Nature in Surgical Endoscopy
- Vol. 26 (2) , 423-430
Stenting for malignant colorectal obstruction: a single-center experience with 101 patients
Self-expanding metal stents (SEMS) are used for colorectal obstruction preoperatively and palliatively. Limited data on the use of stents for obstruction caused by extracolonic malignancies exist, and the results are unclear. Our goal was to evaluate the efficacy and safety of SEMS for patients stented as a bridge to surgery and as palliation for colorectal cancer or extracolonic malignancies. Between 1998 and 2009, a total of 101 patients underwent 108 stenting procedures for malignant colorectal obstruction. The results were studied retrospectively. Of the study cohort, 11 patients were stented as a bridge to surgery. For palliatively stented patients, the etiology of obstruction was colorectal cancer in 66 patients and extracolonic malignancy in 24. Overall technical success was 99% and clinical success 88%. Complications occurred for 20 (20%) patients in 22 of 108 procedures. Complications included perforation (n = 6), recurrent obstruction (n = 8), and stent migration (n = 4). A median time to complication was 81.5 days. The overall stent placement-related mortality was 2/101 (2%). For patients stented as a bridge to surgery, a primary anastomosis in elective operations was achieved for 90% (9/10). In the palliation groups, patients with colorectal cancer had significantly higher clinical success rates than patients with extracolonic malignancies (94% vs. 65%, P = 0.0005). There was no difference in complications, operation, and stoma rates between the palliation groups. SEMS is a safe and effective treatment for patients stented as a bridge to surgery or as palliation due to colorectal cancer. Stents are also useful in relieving obstruction due to extracolonic malignancies, but the clinical failure rate is higher than for colorectal cancer.
- 10 September 2011
- Published by Springer Nature in Surgical Endoscopy
- Vol. 26 (2) , 423-430
Stenting for malignant colorectal obstruction: a single-center experience with 101 patients
Self-expanding metal stents (SEMS) are used for colorectal obstruction preoperatively and palliatively. Limited data on the use of stents for obstruction caused by extracolonic malignancies exist, and the results are unclear. Our goal was to evaluate the efficacy and safety of SEMS for patients stented as a bridge to surgery and as palliation for colorectal cancer or extracolonic malignancies. Between 1998 and 2009, a total of 101 patients underwent 108 stenting procedures for malignant colorectal obstruction. The results were studied retrospectively. Of the study cohort, 11 patients were stented as a bridge to surgery. For palliatively stented patients, the etiology of obstruction was colorectal cancer in 66 patients and extracolonic malignancy in 24. Overall technical success was 99% and clinical success 88%. Complications occurred for 20 (20%) patients in 22 of 108 procedures. Complications included perforation (n = 6), recurrent obstruction (n = 8), and stent migration (n = 4). A median time to complication was 81.5 days. The overall stent placement-related mortality was 2/101 (2%). For patients stented as a bridge to surgery, a primary anastomosis in elective operations was achieved for 90% (9/10). In the palliation groups, patients with colorectal cancer had significantly higher clinical success rates than patients with extracolonic malignancies (94% vs. 65%, P = 0.0005). There was no difference in complications, operation, and stoma rates between the palliation groups. SEMS is a safe and effective treatment for patients stented as a bridge to surgery or as palliation due to colorectal cancer. Stents are also useful in relieving obstruction due to extracolonic malignancies, but the clinical failure rate is higher than for colorectal cancer.